MSI (Microsatellite instability)

Furthermore, STC2 knockdown reduced anoikis-related apoptotic rates in an MDA-MB-231-based anoikis-mimic model in vitro. This study established an anoikis-related gene signature that may improve prognostic stratification and reflect immunotherapy-related features in TNBC.

Integrated profiling of TETs reveals distinct genomic, transcriptomic, and immune features across subtypes of TETs and identifies potentially actionable therapeutic targets that may inform future treatment strategies.

While CRISPR-Cas9 knock-in of MSH3 variants (Exons 21, 22, and 23) in SW620 cells did not alter cell morphology, proliferation, protein localization, or MSH2 binding, we observed genetic changes that collectively underscore the bidirectional nature of STR instability in MSH3-deficient cells and reinforce this protein's pivotal role in suppressing slippage at longer repeat motifs. This study advances our understanding of how MSH3 deficiency contributes to genomic instability beyond canonically defined MSI loci, offering novel insights into the mutational landscapes of MMR-deficient tumors and how these MSH3 mutations can potentially contribute to the outcome of AA CRC patients.

Epinephrine or glial cell line-derived neurotrophic factor also stimulated migration specifically in BRAF-mutated cells. These results emphasize the importance of targeting specific neural signaling pathways and highlight that patient stratification is essential for cancer neuroscience studies.

P2, N=10, Not yet recruiting, Haihua Yuan

Minimal microsatellite shift is commonly detected in MSI-H cases, and some cases are difficult to interpret due to their classification within the equivocal range. Increasing the number of microsatellite loci, combined with visualization graph comparison and integration of mismatch repair protein immunophenotype and histological features, can effectively improve the accuracy of MSI-H interpretation.

Enrichment analysis identified pathways such as RNA transport, spliceosome function, and endocytosis as significantly associated with MEX3C-related genes. These findings establish MEX3C as a pivotal biomarker and potential therapeutic target, warranting further investigation into its mechanistic roles in cancer progression.

P2, N=110, Active, not recruiting, University of Oklahoma | Trial primary completion date: Mar 2026 --> Jun 2026

ICI rechallenge in GC should be regarded as a biomarker-informed investigational strategy rather than a standard of care. Prospective trials, standardized definitions, validated biomarkers, and careful toxicity monitoring are needed.

YORC presents more often with symptoms and advanced disease (M+, N+, EMVI+), yet short-term survival in non-metastatic patients tended to parallel that of older individuals. These findings underscore the need for earlier diagnosis, tailored management, and increased clinical awareness.

Colorectal cancer treatment is increasingly evolving into a precision oncology approach. Integration of molecular biomarkers enables tailored therapy decisions and opens new options, particularly in adjuvant and metastatic settings.

BRAF and RAS mutation occurred in 60% and 14% of the patients with available molecular data, respectively. No patients harbored HER2 amplification, suggesting that the co-occurrence of HER2 amplification and dMMR/MSI is essentially anecdotal, making therefore HER2 testing in this subgroup less compelling.